Aims: The efficacy of endovenous treatments for venous reflux has been demonstrated in numerous randomised clinical trials, although significant heterogeneity may exist between studies. The aim of this study was to assess the heterogeneity in reporting between randomised clinical trials investigating endovenous treatments for patients with varicose veins. Methods: A literature search of the Pubmed, Cochrane and Google Scholar databases was performed using appropriate search terms. Randomised clinical trials published between January 1968 and June 2009 evaluating endovenous interventions for varicose veins were included and relevant abstracts and full text articles were reviewed. Published study reports were evaluated against recommended reporting standards published by the American Venous Forum in 2007. Results: Twenty-eight randomised trials fulfilled the inclusion criteria. Median patient age (reported in 20/28 studies) ranged from 33 to 54 years. The CEAP classification was presented in 17/28 studies and the proportion of patients with C2 disease ranged from 6.3% to 83.5%. A total of 31 different outcome measures were utilised. This included 13 different questionnaires, varicose vein recurrence at 38 time points and 30 categories of complications. Duplex ultrasonography was used in 21/28 trials to assess recurrence. Quality of life was only evaluated in 11 studies and the follow-up period ranged from 3 weeks to 10 years. Conclusions: Meaningful comparison across randomised studies of endovenous treatments is made difficult by considerable variations in study populations and outcome measures between trials. This highlights the need for the use of prospectively agreed population selection, and reporting standards for outcome measures in randomised clinical assessments of new treatments. ª
Introduction
Varicose veins and associated complications are extremely common, with a UK adult prevalence of 25e33%. 1, 2 Patients may be asymptomatic, although pain, swelling, eczema, skin pigmentation, and eventual ulceration are common symptoms. 1 For all severities of disease, treatment of superficial venous reflux has been shown to improve quality of life (QOL) in patients with varicose veins. 3 A variety of surgical and endovenous modalities are currently available for the treatment of superficial venous reflux. Traditional surgery involves ligation and stripping of the refluxing great (GSV) or small saphenous veins (SSV) and ambulatory phlebectomy, although endovenous technologies to ablate refluxing veins have become popular. Techniques include ultrasound guided foam sclerotherapy (UGFS), radiofrequency ablation (RFA) and endovenous laser ablation (EVLA). These interventions have been evaluated in numerous randomised clinical studies, although the heterogeneity of study populations and outcomes assessed is unknown.
Reporting standards in venous disease were published originally by the American Venous Forum in 1988, 4 and further modified in 1995 5 and 2004; 6 the 2004 publication separated CEAP C4 into C4a and C4b. A further guide was published for reporting standards in endovenous ablation for venous insufficiency in 2007. 7 The purpose of these standards was to encourage uniformity in the reporting of trials assessing treatment modalities for venous disease. The aim of this study was to assess the heterogeneity in reporting between randomised clinical trials investigating endovenous treatments for patients with varicose veins.
Methods
A literature search of the Pubmed, Cochrane and Google Scholar databases was performed, using the search terms "varicose veins", "ligation", "saphenous vein", "sclerosant foam", "cryosurgery", "sclerotherapy", "endovenous laser" and "radiofrequency ablation" within 'All fields' with appropriate search limits. All abstracts were reviewed and relevant full text articles were obtained. Reference lists and 'related articles' were also scrutinised to identify all relevant publications. Only randomised trials evaluating endovenous interventions for varicose veins published between January 1968 and June 2009 were included. Nonrandomised trials were not included. Other exclusion criteria were:
Trials where no patient group received an endovenous treatment, e.g. comparing two different surgical methods All groups within the trial received different forms of the same endovenous treatment, e.g. different sclerosants Studies of treatments for venous ulceration From each study, details of patient demographics, anatomical information, follow-up period and outcome measures were recorded. Study details were compared to the "recommended reporting standards" published by the American Venous Forum in 2007. 7 
Results

Results of literature search
A total of 2384 results were obtained from the search criteria, of which 28 randomised trials fulfilled the inclusion criteria ( Fig. 1 ). All studies were published between 1968 and 2009. Details of the included studies are presented in Table 1 .
Study populations, demographics and baseline clinical characteristics
Patient age was recorded in 20 of the 28 studies (median age range 33e54 years between studies) and gender was reported in 23 of 28. Other important characteristics for comparison between the patients in various studies such as co-morbidities and body mass index (BMI) were poorly reported. The CEAP classification was presented in 17 of the 28 studies, although only nine of these provided the exact distribution of patients in to CEAP groups 1e6.
Outcome measures assessed
Within the studies included, numerous measures of treatment efficacy were assessed. Thirty categories of complications were recorded with infection, phlebitis, pain, haematoma and paraesthesia being the most common ( Table 2 ). The follow-up periods between studies ranged from 3 weeks to 10 years. Recurrence of varicose veins was assessed at 38 different time points ranging from one day to 10 years. Twenty-five studies measured recurrence as an end-point of treatment, and of these, 21 used venous duplex ultrasonography as an objective assessment of recurrence. Three studies measured ambulatory venous pressure or refill time in addition to Duplex. Five of the seven studies that did not use duplex as a part of their assessment of recurrence were all pre-1980, at which time duplex scanning was not routinely available. The remaining two studies were not assessing recurrence as an endpoint.
Thirteen different validated questionnaires were used and several additional non-validated questionnaires were also employed. Validated QOL assessments were not available until 1993 (when Short Form-36 was introduced). 8, 9 Of the 23 trials were published post-1993, only 11 assessed QOL with a validated questionnaire.
Discussion
This study demonstrated that the published randomised trials evaluating endovenous treatments vary hugely in reporting and outcome measures assessed. Meaningful comparison across randomised studies is made difficult by the variations in study design and lack of adherence to published reporting standards. 7 Few studies provided relevant demographic data of their subjects. Factors such as BMI 10 and occupation 11 are known risk factors for varicose veins and associated symptoms and also for subsequent complications from treatment, such as wound infection. 12 This highlights the necessity for accurate recording of population characteristics. Moreover, outcomes may vary hugely depending on CEAP grade. Only nine studies provided detailed CEAP information, and only 2 studies limited their patient selection to a single CEAP class. A separate analysis for each varicose vein clinical class and access to the raw data may improve our understanding of clinical outcomes in patients with different CEAP grades.
Kundu et al 7 recommend that clinical and duplex follow-up should be at uniform intervals, typically within the first 3 days post-procedure, then at 1 month, 1 year after treatment, and annually thereafter (1e3 years for mid-term follow-up, or greater than 3 years for long term follow-up). The wide variation in time points seen within the trials makes direct comparison of outcomes difficult to interpret. The use of QOL questionnaires is another area where a significant deficiencies were seen. Anatomical measures of treatment efficacy in isolation, in this context, are not a suitable measure of treatment efficacy. The fact that seven different types of QOL questionnaires were in use highlights the variety of available Table 2 Included randomised controlled trials in varicose vein intervention, with summary of treatment modalities compared, basic demographic details recorded, quality of life assessment and time points for follow-up. These studies have been separated into post-2007 and pre-2007, to reflect before and after the publication of the American Venous Forum reporting standards. 7 
Demographic
Anatomical outcome measures within this particular category. The variation in reporting of complications represents the broad range experienced by different clinicians. Reporting of even common complications was inconsistent, with only eight studies specifically assessing haematoma formation postprocedure, and six studies mentioning incidence of DVT. The heterogeneity seen within these trials can be explained largely by the fact that our understanding of the management of varicose veins has become progressively more sophisticated since the 1960s initiated by early randomised trials in this field. 40 The advent of new technologies for the assessment and treatment of varicose veins, and methods for recording treatment efficacy has resulted in a change in methodology in randomised trials. Attempts were first made in 1994 4 to produce guidelines, although adherence to these and other subsequent guidelines has been slow.
The implications of this study extend beyond trials pertaining to varicose vein treatment. Reporting of population and outcome data in randomised trials of new interventions should be standardised in order to allow reliable comparison between studies. Although we have only assessed trials concerning endovenous treatment of varicose veins, similar studies could be carried out for the treatment of venous ulceration, or in fact for any modality for which a clearly defined standard exists.
A limitation of this study is the fact that the most recent reporting standards in endovenous ablation were published in 2007, 7 whereas most published studies included in this review were published before 2007. If studies pre and post 2007 are considered separately, significant differences can be seen. The recording of demographics is improved. All nine of the post 2007 studies recorded patient's age, and 8 of the 9 gave details of the gender. 3 studies post 2007 still did not however use a validated QOL questionnaire, which highlights that despite improvements in reporting standards in certain aspects, there is still considerable lack of adherence to AVF guidelines in crucial areas. It would therefore be important to see if randomised trials in the future are more adherent to the recommended standards. In conclusion, in trials evaluating endovenous interventions for superficial venous reflux, significant variations exist in the reporting of baseline characteristics, outcome measures, length of follow-up. This highlights the need for agreed reporting standards and greater adherence to these standards, as this would allow greater objectivity in the assessment of new technologies for the treatment of varicose veins.
